Drug & intervention
ixabepilone
RxCUI 337523
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Ixabepilone
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownBreast Cancer Treatment Based on Organ-like CultureNCT03925233 · 2019-01-02
UNKNOWNPharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor BiopsyNCT03393741 · 2018-01-29
TERMINATEDA Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineNCT02915744 · 2016-11-01
COMPLETEDInvestigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerNCT01349088 · 2013-12-01
WITHDRAWNIxabepilone and SBRT For Metastatic Breast CancerNCT01818999 · 2013-08-01
WITHDRAWNChloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)NCT01446016 · 2011-09-01
COMPLETEDA Study of LY2523355 in Participants With Breast CancerNCT01416389 · 2011-08-01
COMPLETEDRadiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After SurgeryNCT01079793 · 2010-05-26
WITHDRAWNIxabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerNCT01084057 · 2010-05-17
COMPLETEDTrial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)NCT01057212 · 2010-02-01
TERMINATEDIxabepilone + Carboplatin Metastatic Breast CancerNCT01075100 · 2010-01-01
COMPLETEDStudy of Pazopanib and Ixabepilone in Patients With Solid TumorsNCT01012362 · 2009-12-01
TERMINATEDCalcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast CancerNCT00998738 · 2009-11-01
TERMINATEDCarboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With ChemotherapyNCT00998101 · 2009-07-01
WITHDRAWNTrial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast CancerNCT00924352 · 2009-06-01
COMPLETEDPhase I Combination Ixabepilone + CisplatinNCT00832117 · 2009-05-01
COMPLETEDIxabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerNCT00866905 · 2009-04-01
COMPLETEDA Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerNCT00879086 · 2009-03-31
COMPLETEDIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyNCT00877500 · 2009-03-30
ACTIVE_NOT_RECRUITINGPhase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast CancerNCT00825734 · 2009-03-01
COMPLETEDNeoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate CancerNCT00828308 · 2009-02-01
COMPLETEDIxabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast CancerNCT00765765 · 2009-02-01
TERMINATEDNeoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast CancerNCT00821886 · 2009-02-01
COMPLETEDTrial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)NCT00790894 · 2008-11-01
TERMINATEDPaclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerNCT00785291 · 2008-10-13
COMPLETEDNeo-Adjuvant Study in Triple Negative Breast Cancer PatientsNCT01097642 · 2008-10-10
COMPLETEDIxabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerNCT00741988 · 2008-09-01
COMPLETEDFEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BCNCT00751868 · 2008-09-01
COMPLETEDRandomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerNCT00633464 · 2008-06-01
COMPLETEDPhase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast CancerNCT00593827 · 2008-05-01
COMPLETEDA Study of Ixabepilone Before Surgery for High-Risk Localized Prostate CancerNCT00672009 · 2008-04-01
TERMINATEDParicalcitol and Chemotherapy in Treating Women With Metastatic Breast CancerNCT00637897 · 2008-03-01
COMPLETEDA Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerNCT00568022 · 2008-02-01
COMPLETEDA Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerNCT00490646 · 2008-02-01
COMPLETEDPhase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of NeuronsNCT00627978 · 2007-11-01
COMPLETEDStudy to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast CancerNCT00455533 · 2007-10-01
COMPLETEDSafety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerNCT00630032 · 2007-09-01
COMPLETEDA Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An AnthracyclineNCT01027208 · 2006-12-01
COMPLETEDPhase I Combination w/ EpirubicinNCT00322374 · 2006-08-01
COMPLETEDTreating Patients With Metastatic Prostate Cancer Not Responding to Hormone and ChemotherapyNCT00331344 · 2006-04-01
COMPLETEDConditions being studied
Breast Cancer19Metastatic Breast Cancer14Stage IV Breast Cancer6Prostate Cancer4Recurrent Breast Cancer4Adenocarcinoma of the Prostate3Recurrent Prostate Cancer3Stage IV Prostate Cancer3Breast Neoplasms2HER2-positive Breast Cancer2HER2/Neu Negative2Lung Cancer2Male Breast Cancer2Recurrent Breast Carcinoma2Adenocarcinoma1Bilateral Breast Carcinoma1Breast Cancer Organoids1Carcinoma1Colon Cancer1Estrogen Receptor Negative1
Research locations
New YorkNew York, United States10HoustonTexas, United States8BethesdaMaryland, United States7BostonMassachusetts, United States7NashvilleTennessee, United States7DallasTexas, United States6MinneapolisMinnesota, United States6CincinnatiOhio, United States5Fort MyersFlorida, United States5Los AngelesCalifornia, United States5PortlandOregon, United States5San FranciscoCalifornia, United States5
Leading sponsors
R-Pharm10National Cancer Institute (NCI)8SCRI Development Innovations, LLC4Memorial Sloan Kettering Cancer Center2The Methodist Hospital Research Institute2University of Texas Southwestern Medical Center2Accelerated Community Oncology Research Network1Bristol-Myers Squibb1Brown University1Cedars-Sinai Medical Center1City of Hope Medical Center1Consorzio Oncotech1Eisai Inc.1Eli Lilly and Company1Hellenic Cooperative Oncology Group1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.